ABNCoV2 cVLP based C…(AdaptVac) Drug Due Diligence 2026

This ABNCoV2 cVLP based COVID-2019 vaccine (AdaptVac) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether ABNCoV2 cVLP based COVID-2019 vaccine (AdaptVac) can convert its Virus-like particle vaccine, Prophylactic vaccine profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	ABNCoV2 cVLP based COVID-2019 vaccine (AdaptVac) (query alias: ABNCoV2 cVLP based COVID-2019 vaccine (AdaptVac))
Modality / target	Virus-like particle vaccine, Prophylactic vaccine; SARS-CoV-2 S protein; SARS-CoV-2 S protein inhibitors, Immunostimulants
Highest global status	Phase 2
Originator	Adaptvac ApS
Active developers	Adaptvac ApS

The MCP disease footprint includes COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05329220	Phase 3	Completed	4205	Primary endpoint not disclosed in English source
NCT05077267	Phase 2	Completed	197	Primary endpoint not disclosed in English source
NCT04839146	Phase 1	Completed	45	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Seronegative and Seropositive Adult Subjects

Phase 2; n=197; evaluation: Not stated in English source. Reported fields: Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Index Virus Neutralizing Antibody Titers at 2 Weeks After the Last Vaccination(Geometric Mean) = 516.7 Titer (95%CI, 309.0 - 864.0); Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Index Virus Neutralizing Antibody Titers at 2 Weeks After the Last Vaccination(Geometric Mean) = 970.9 Titer (95%CI, 804.1 - 1172.3)

Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Phase 2; n=41; evaluation: Positive. Reported fields: Efficacy = Six months post the booster vaccination with ABNCoV2, the neutralization antibody titers against Wuhan and the Omicron variant remained high and at levels associated with a greater than 90% efficacy.

BAVARIAN NORDIC REPORTS INITIAL RESULTS FROM FIRST-IN-HUMAN TRIAL OF COVID-19 VACCINE

Phase 1/2; n=45; evaluation: Positive. Reported fields: SAE = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

ABNCoV2 cVLP based COVID-2019 vaccine (AdaptVac) addresses COVID-19. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Virus-like particle vaccine, Prophylactic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-05-06	Bavarian Nordic Enters Agreement With AdaptVac To Advance COVID-19 Vaccine Program	Preclinical	US$4.4M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Vaccines comprising virus-like particles displaying SARS-COV-2 antigens and methods of use”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO